PharmaPoint: Crohn s Disease - Global Drug Forecast and Market Analysis to 2026

  • ID: 4438979
  • Report
  • Region: Global
  • 226 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Celgene
  • Galapagos
  • Johnson & Johnson
  • Roche
  • Shire
  • MORE
PharmaPoint: Crohn’s Disease - Global Drug Forecast and Market Analysis to 2026

Summary

Inflammatory bowel disease (IBD) refers to two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area. However, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The disease also may affect only some segments of the intestinal tract while leaving normal segments between the affected areas.

In 2016, it is estimated that the global CD market was valued at over US$9 billion across the 7MM. By the end of the forecast period in 2026, sales across these markets will have grown steadily to reach almost US$13.5 billion, representing a Compound Annual Growth Rate (CAGR) of around 3.8% over the 10-year timeframe, which includes six new market entrants and the launch of biosimilars.

Major growth drivers in the CD market over the forecast period include:
  • The anticipated launches of interleukin (IL) inhibitors and anti-integrin therapies, including AbbVie’s risankizumab, Genentech’s etrolizumab, and Takeda’s subcutaneous Entyvio (Entyvio SC), as well as Galapagos/Gilead’s filgotinib, Celgene’s mongersen sodium, and Shire’s SHP-647, will provide more treatment options for physicians to choose from.
  • The number of diagnosed prevalent CD cases will increase to over 1.8 million in 2026 at an annual growth rate (AGR) of 2.3%. Total treated cases will grow to almost 1.2 million at an AGR of 2.3% during the 10-year period of 2016-2026.
  • Strong uptake of J&J’s IL-12/23 inhibitor Stelarawill continue, generating sales of about US$1.2 billion across the 7MM in 2026.
  • The high unmet need for improved medical management of perianal fistulas presents an untapped market opportunity.
The report "PharmaPoint: Crohn’s Disease - Global Drug Forecast and Market Analysis to 2026", providesoverview of CD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In depth, this report provides the following:
  • Topline CD market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CD therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Scope
  • Overview of CD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline CD market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CD therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Celgene
  • Galapagos
  • Johnson & Johnson
  • Roche
  • Shire
  • MORE
1 Table of Contents

2 Executive Summary
2.1 Launch of Non-Anti-TNF Therapies Will Fuel CD Market Growth to 2026
2.2 R&D and Corporate Strategies Will Be Focused on the Competitive Biologics Space
2.3 A Number of Clinical Unmet Needs Exist in the CD Treatment Realm
2.4 Treatments for the Management of Perianal Fistulas Remain Elusive
2.5 Novel Biologics and Biosimilars Will Reshape the CD Competitive Landscape
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Biomarkers/Targets of Interest
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Crohn’s Disease
5.6 Alternate Epidemiological Forecast for Crohn’s Disease (2016-2026)
5.7 Discussion

6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.3 US
6.4 5EU
6.5 Japan

7 Competitive Assessment
7.1 Overview
7.2 Remicade (infliximab)
7.3 Humira (adalimumab)
7.4 Cimzia (certolizumab pegol)
7.5 Entyvio (vedolizumab)
7.6 Stelara (ustekinumab)
7.7 Inflectra/Remsima (infliximab biosimilar)
7.8 Renflexis/Flixabi (infliximab biosimilar)
7.9 Amjevita/Amgevita (adalimumab biosimilar)
7.10 Biosimilar Assessment
7.11 Other Therapeutic Classes

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting
8.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis
8.4 Improve Medical Management of Perianal Fistulas
8.5 Patient Adherence to Maintenance Therapy

9 Pipeline Assessment
9.1 Overview
9.2 Clinical Trial Mapping
9.3 Promising Drugs in Clinical Development
9.4 Etrolizumab
9.5 Mongersen
9.6 Filgotinib
9.7 SHP-647
9.8 Risankizumab
9.9 Other Drugs in Early-Stage Development
9.10 Other Promising Drugs in Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Johnson & Johnson
10.4 AbbVie
10.5 UCB
10.6 Takeda
10.7 Roche
10.8 Celgene
10.9 Galapagos
10.10 Shire

11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - KOLs Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About
12.8 Contact
12.9 Disclaimer

List of Tables
Table 1: Crohn’s Disease: Key Metrics in the 7MM
Table 2: Symptoms of Crohn’s Disease
Table 3: Risk Factors and Comorbidities for Crohn’s Disease
Table 4: 7MM, Diagnosed Incident Cases of CD, All Ages, Both Sexes, Select Years 2016-2026
Table 5: 7MM, Diagnosed Prevalent Cases of CD, Men and Women, All Ages, Select Years 2016-2026
Table 6: Treatment Guidelines for Crohn’s Disease
Table 7: Most Prescribed Drugs for Crohn’s Disease by Class in the Global Markets, 2016
Table 8: Country Profile - US
Table 9: Country Profile - 5EU
Table 10: Country Profile - Japan
Table 11: Product Profile - Remicade
Table 12: Safety Data From the ACCENT II Study Up to Week 54
Table 13: Remicade SWOT Analysis, 2017
Table 14: Product Profile - Humira
Table 15: Humira SWOT Analysis, 2017
Table 16: Product Profile - Cimzia
Table 17: Cimzia SWOT Analysis, 2017
Table 18: Product Profile - Entyvio
Table 19: Efficacy Data From the Phase III GEMINI II Maintenance Study
Table 20: Safety Data for Entyvio from the GEMINI II Study
Table 21: Entyvio SWOT Analysis, 2017
Table 22: Product Profile - Stelara
Table 23: Efficacy Data From the IM-UNITI Phase III Study
Table 24: Safety Data for Stelara from the IM-UNITI Study
Table 25: Stelara SWOT Analysis, 2017
Table 26: Product Profile - Inflectra/Remsima
Table 27: Inflectra/Remsima SWOT Analysis, 2017
Table 28: Product Profile - Renflexis/Flixabi
Table 29: Renflexis/Flixabi SWOT Analysis, 2017
Table 30: Product Profile - Amjevita
Table 31: Amjevita SWOT Analysis, 2017
Table 32: Marketed and Pipeline Biosimilars for CD, 2017
Table 33: Biosimilar Legislation Across the 7MM
Table 34: Summary of Minor Therapeutic Classes, 2017
Table 35: Comparison of Therapeutic Classes in Development for Crohn’s Disease, 2016-2026
Table 36: Product Profile - Etrolizumab
Table 37: Phase II Safety Data for Etrolizumab in UC
Table 38: Etrolizumab SWOT Analysis, 2017
Table 39: Product Profile - Mongersen
Table 40: Phase II Efficacy Data for Mongersen Sodium
Table 41: Phase II Safety Data for Mongersen Sodium
Table 42: Mongersen Sodium SWOT Analysis, 2017
Table 43: Product Profile - Filgotinib
Table 44: Phase II Efficacy Data for Filgotinib from the FITZROY Study
Table 45: Phase II Safety Data for Filgotinib
Table 46: Filgotinib SWOT Analysis, 2017
Table 47: Product Profile - SHP-647
Table 48: Phase II Efficacy Data for SHP-647 from the OPERA Study
Table 49: SHP-647 SWOT Analysis, 2017
Table 50: Product Profile - Risankizumab
Table 51: Phase II Safety Data for Risankizumab
Table 52: Risankizumab SWOT Analysis, 2017
Table 53: Drugs in Development for CD, 2017
Table 54: Drugs in Development for Crohn’s Disease, 2017
Table 55: Key Companies in the Crohn’s Disease Market in the 7MM, 2017
Table 56: J&J’s Disease Portfolio Assessment, 2017
Table 57: J&J SWOT Analysis, 2017
Table 58: AbbVie’s Disease Portfolio Assessment, 2017
Table 59: AbbVie SWOT Analysis, 2017
Table 60: UCB’s Disease Portfolio Assessment, 2017
Table 61: UCB SWOT Analysis, 2017
Table 62: Takeda’s Disease Portfolio Assessment, 2017
Table 63: Takeda SWOT Analysis, 2017
Table 64: Roche/Genentech’s Disease Portfolio Assessment, 2017
Table 65: Roche/Genentech SWOT Analysis, 2017
Table 66: Celgene’s Disease Portfolio Assessment, 2017
Table 67: Celgene SWOT Analysis, 2017
Table 68: Galapagos’ Disease Portfolio Assessment, 2017
Table 69: Galapagos SWOT Analysis, 2017
Table 70: Shire’s Disease Portfolio Assessment, 2017
Table 71: Shire SWOT Analysis, 2017
Table 72: Crohn’s Disease Market - Global Drivers and Barriers, 2016-2026
Table 73: Key Events Impacting Sales for Crohn’s Disease in the US, 2016-2026
Table 74: Crohn’s Disease Market - Drivers and Barriers in the US, 2016-2026
Table 75: Key Events Impacting Sales for Crohn’s Disease in the 5EU, 2016-2026
Table 76: Crohn’s Disease Market -Drivers and Barriers in the 5EU, 2016-2026
Table 77: Key Events Impacting Sales for Crohn’s Disease in Japan, 2016-2026
Table 78: Crohn’s Disease Market - Global Drivers and Barriers in Japan, 2016-2026
Table 79: Key Historical and Projected Launch Dates for Crohn’s Disease
Table 80: Key Historical and Projected Patent Expiry Dates for Crohn’s Disease
Table 81: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global (7MM) Sales Forecast by Country for Crohn’s Disease in 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in Crohn’s Disease During the Forecast Period
Figure 3: Crohn’s Disease, Late-Stage Pipeline Agents, Competitive Assessment, 2016-2026
Figure 4: 7MM, Age-Adjusted Diagnosed Prevalence of CD (%), Men, All Ages, 2006 to 2026
Figure 5: 7MM, Age-Adjusted Diagnosed Prevalence (%) of CD, Women, All Ages, 2006-2026
Figure 6: Sources Used and Not Used, Diagnosed Incident Cases of CD
Figure 7: Sources Used and Not Used, Diagnosed Prevalent Cases of CD
Figure 8: Sources Used, Diagnosed Prevalent Cases of CD with Comorbid Autoimmune Diseases
Figure 9: 7MM, Age-Specific Diagnosed Prevalent Cases of CD, Both Sexes, 2016
Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of CD, All Ages, 2016
Figure 11: 7MM, Diagnosed Prevalent Cases of CD by Severity, Both Sexes, All Ages, 2016
Figure 12: 7MM, Diagnosed Prevalent Cases of CD with PsO, Ankylosing Spondylitis, and Pyoderma Gangrenosum, Both Sexes, All Ages, 2016
Figure 13: US and 5EU, Alternate Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016
Figure 14: Germany, Spain, Italy, and the UK, Alternate Diagnosed Prevalent Cases of CD, Both Sexes, All Ages, 2016
Figure 15: Unmet Need and Opportunity in Crohn’s Disease, 2017
Figure 16: Overview of the Development Pipeline for CD
Figure 17: CD Therapeutics - Phase III Commercial Clinical Trials by Class of Therapy, 2017
Figure 18: Key Phase II/III Trials for Promising Pipeline Agents for Crohn’s Disease, 7MM, 2016-2026
Figure 19: Crohn’s Disease, Late-Stage Pipeline Agents, Competitive Assessment, 2016-2026
Figure 20: Clinical and Commercial Positioning of Etrolizumab
Figure 21: Clinical and Commercial Positioning of Mongersen Sodium
Figure 22: Clinical and Commercial Positioning of Filgotinib
Figure 23: Clinical and Commercial Positioning of SHP-647
Figure 24: Clinical and Commercial Positioning of Risankizumab
Figure 25: Global Sales of Branded Products for Crohn’s Disease by Company in 2016 and 2026
Figure 26: Analysis of the Company Portfolio Gap in Crohn’s Disease During the Forecast Period
Figure 27: Global (7MM) Sales Forecast by Country for Crohn’s Disease in 2016 and 2026
Figure 28: Sales Forecast by Class for Crohn’s Disease in the US in 2016 and 2026
Figure 29: Sales Forecast by Class for Crohn’s Disease in the 5EU in 2016 and 2026
Figure 30: Sales Forecast by Class for Crohn’s Disease in Japan in 2016 and 2026
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Johnson & Johnson
  • AbbVie
  • UCB
  • Takeda
  • Roche
  • Celgene
  • Galapagos
  • Shire
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll